Literature DB >> 28011077

Top-down and bottom-up analysis of commercial enoxaparins.

Xinyue Liu1, Kalib St Ange2, Lei Lin3, Fuming Zhang4, Lianli Chi5, Robert J Linhardt6.   

Abstract

A strategy for the comprehensive analysis of low molecular weight (LMW) heparins is described that relies on using an integrated top-down and bottom-up approach. Liquid chromatography-mass spectrometry, an essential component of this approach, is rapid, robust, and amenable to automated processing and interpretation. Nuclear magnetic resonance spectroscopy provides complementary top-down information on the chirality of the uronic acid residues comprising a low molecular weight heparin. Using our integrated approach four different low molecular weight heparins prepared from porcine heparin through chemical β-eliminative cleavage were comprehensively analyzed. Lovenox™ and Clexane™, the innovator versions of enoxaparin marketed in the US and Europe, respectively, and two generic enoxaparins, from Sandoz and Teva, were analyzed. The results which were supported by analysis of variation (ANOVA), while showing remarkable similarities between different versions of the product and good lot-to-lot consistency of each product, also detects subtle differences that may result from differences in their manufacturing processes or differences in the source (or parent) porcine heparin from which each product is prepared.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bottom-up; HILIC-ESI-FTMS; LMW heparin; NMR; Top-down

Mesh:

Substances:

Year:  2016        PMID: 28011077     DOI: 10.1016/j.chroma.2016.12.021

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  3 in total

Review 1.  Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.

Authors:  Jacobus R B J Brouwers; Jeanine E Roeters van Lennep; Maarten J Beinema
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

Review 2.  Recent advances in biotechnology for heparin and heparan sulfate analysis.

Authors:  Meng Qiao; Lei Lin; Ke Xia; Jun Li; Xing Zhang; Robert J Linhardt
Journal:  Talanta       Date:  2020-06-14       Impact factor: 6.057

3.  Commercial Low Molecular Weight Heparins - Patent Ecosystem and Technology Paradigm for Quality Characterization.

Authors:  Zarina Iqbal; Saima Sadaf
Journal:  J Pharm Innov       Date:  2022-07-28       Impact factor: 2.538

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.